Clinical factors associated with early progression and grade 3-4 toxicity in patients with advanced non-small-cell lung cancers treated with nivolumab.
Coraline DumenilMarie-Ange MassianiJennifer DumoulinViolaine GiraudSylvie LabruneThierry ChinetEtienne Giroux-LeprieurPublished in: PloS one (2018)
Our results suggest that nivolumab is not beneficial or safe for patients with PS 2 and symptomatic brain metastases.